The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018.

Blood Cancer J · 2023 · PMC9876983 · PMID 36697388

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Patients with stage II and stage IIIa disease seem to benefit the most from new therapies; OS in this patient population improved after 2010 (although it did not reach statistical significance for stage II), probably due to the introduction of bortezomib.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.